Literature DB >> 8733001

Modulation of hypertensive heart disease by estrogen.

C Grohé1, S Kahlert, K Löbbert, R Meyer, K W Linz, R H Karas, H Vetter.   

Abstract

UNLABELLED: Left ventricular hypertrophy is an independent risk factor for morbidity and mortality in patients with hypertensive heart disease. Cardiac hypertrophy, associated with increased cardiac fibrosis and myocardial relaxation impairment, shows gender-based differences with significantly higher mortality in men. The role of estrogen in the pathogenesis of this process is poorly understood. After our previous demonstration that cardiac myocytes and fibroblasts contain functional estrogen receptors, we therefore investigated: 1) the influence of different estrogen metabolites on cardiac fibroblast growth; 2) the influence of different estrogen metabolites on the expression of the immediate early gene c-Fos; 3) the influence of estrogen on the L-type calcium channel in cardiomyocytes.
METHODS: 1) Neonatal rat cardiac fibroblasts were incubated with 17 beta-estradiol, estrone, 2-hydroxyestrone, and 2-methoxyestradiol (all 10(-9) M). Bromodeoxyuridine incorporation was measured after 24 h. 2) c-Fos expression was demonstrated by immunoblotting. 3) L-type (Ca2+) current with and without 17 beta-estradiol was assessed in adult guinea pig cardiomyocytes by whole cell patch clamp.
RESULTS: Cardiac fibroblast growth was stimulated by estrogen metabolites with 2-hydroxyestrone as the most potent activator; in addition, 10(-5) M 17 beta-estradiol reduced the L-type Ca2+ current by about 20% in cardiomyocytes.
CONCLUSIONS: Estrogen induces both short term effects (non-genomic) and long term effects (genomic) on the heart and may therefore account for gender- and age-based differences in hypertensive heart disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8733001     DOI: 10.1016/0039-128x(96)00014-1

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  7 in total

Review 1.  Sex is a potent modifier of the cardiovascular system.

Authors:  Leslie A Leinwand
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

2.  Membrane ERα attenuates myocardial fibrosis via RhoA/ROCK-mediated actin remodeling in ovariectomized female infarcted rats.

Authors:  Tsung-Ming Lee; Shinn-Zong Lin; Nen-Chung Chang
Journal:  J Mol Med (Berl)       Date:  2013-11-29       Impact factor: 4.599

Review 3.  Rapid estrogen actions on ion channels: A survey in search for mechanisms.

Authors:  Lee-Ming Kow; Donald W Pfaff
Journal:  Steroids       Date:  2016-03-03       Impact factor: 2.668

4.  Raloxifene acutely suppresses ventricular myocyte contractility through inhibition of the L-type calcium current.

Authors:  Reginald Liew; Mark A Stagg; Kenneth T MacLeod; Peter Collins
Journal:  Br J Pharmacol       Date:  2004-03-15       Impact factor: 8.739

5.  Increased expression of the cardiac L-type calcium channel in estrogen receptor-deficient mice.

Authors:  B D Johnson; W Zheng; K S Korach; T Scheuer; W A Catterall; G M Rubanyi
Journal:  J Gen Physiol       Date:  1997-08       Impact factor: 4.086

6.  Male and female hypertrophic rat cardiac myocyte functional responses to ischemic stress and β-adrenergic challenge are different.

Authors:  James R Bell; Claire L Curl; Tristan W Harding; Martin Vila Petroff; Stephen B Harrap; Lea M D Delbridge
Journal:  Biol Sex Differ       Date:  2016-07-07       Impact factor: 5.027

7.  Single acute stress-induced progesterone and ovariectomy alter cardiomyocyte contractile function in female rats.

Authors:  Judit Kalász; Enikő Pásztor Tóth; Beáta Bódi; Miklós Fagyas; Attila Tóth; Bhattoa Harjit Pal; Sandor G Vari; Marta Balog; Senka Blažetić; Marija Heffer; Zoltán Papp; Attila Borbély
Journal:  Croat Med J       Date:  2014-06-01       Impact factor: 1.351

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.